The Ductal Carcinoma In Situ drugs in development market research report provides comprehensive information on the therapeutics under development for Ductal Carcinoma In Situ, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Ductal Carcinoma In Situ. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Ductal Carcinoma In Situ and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Ductal Carcinoma In Situ by six companies/universities/institutes. The top development phase for Ductal Carcinoma In Situ is phase ii with six drugs in that stage. The Ductal Carcinoma In Situ pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Ductal Carcinoma In Situ pipeline products market are: Marker Therapeutics, F. Hoffmann-La Roche and Atossa Therapeutics.
The key targets in the Ductal Carcinoma In Situ pipeline products market include Receptor Tyrosine Protein Kinase ERBB 2 (Metastatic Lymph Node Gene 19 Protein or Proto Oncogene Neu or Proto Oncogene C ErbB 2 or Tyrosine Kinase Type Cell Surface Receptor HER2 or p185erbB2 or HER2 or CD340 or ERBB2 or EC 2.7.10.1), Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2 (Metastatic Lymph Node Gene 19 Protein or Proto Oncogene Neu or Proto Oncogene C ErbB 2 or Tyrosine Kinase Type Cell Surface Receptor HER2 or p185erbB2 or HER2 or CD340 or ERBB2 or EC 2.7.10.1), and Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22).
The key mechanisms of action in the Ductal Carcinoma In Situ pipeline product include Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2 (Metastatic Lymph Node Gene 19 Protein or Proto Oncogene Neu or Proto Oncogene C ErbB 2 or Tyrosine Kinase Type Cell Surface Receptor HER2 or p185erbB2 or HER2 or CD340 or ERBB2 or EC 2 with two drugs in Phase III. The Ductal Carcinoma In Situ pipeline products include seven routes of administration with the top ROA being Intradermal and four key molecule types in the Ductal Carcinoma In Situ pipeline products market including Subunit Vaccine, and Small Molecule.
Ductal Carcinoma In Situ overview
Ductal carcinoma in situ (DCIS), also referred to as intraductal carcinoma, is a non-invasive breast cancer characterized by a proliferation of abnormal epithelial cells confined within the basement membrane. Disruption of the basement membrane layer would change the diagnosis from DCIS to invasive breast cancer. DCIS is considered to be a precursor for invasive breast cancer.
For a complete picture of Ductal Carcinoma In Situ’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
